Organic Active Ingredients TRIZ Cases

This composition uses hypertonic saline and local delivery to limit systemic NSAID effects while targeting respiratory and oral pathogens.

This case examines route-specific 5-MeO-DMT dosing to address limited anxiety treatment effectiveness and compliance.

This case uses enteric coating and scored dose units to match three-times-daily efficacy with twice-daily dosing.

This case uses intravenous, intramuscular, or subcutaneous 5-MeO-DMT to address bipolar symptoms with rapid action and durable response.

CPI-818 selectively targets ITK to increase Th1 cells, limit Th2 cytokines, and address cancer, autoimmune disease, and allergies.

This case uses alpha-polyglutamated pralatrexate liposomes to improve tumor delivery, intracellular retention, and efflux resistance.

This case uses an IAP ligand, linker, and target ligand to improve degradation of intracellular kinases such as ROCK2 and FAK.

This case uses ABCB1 expression to guide tepoxalin treatment, turning a chemotherapy resistance mechanism into selective cancer-cell killing.

L-arginine or meglumine and selected excipients improve CCR3 antagonist stability during granulation and oral formulation manufacture.

This case uses subcutaneous IL-31RA antibody dosing at extended intervals to relieve pruritus while reducing medication and hospital visits.

Lysine cores, PEG chains, amide bonds, and click chemistry enable modular constructs with controlled targeting and effector combinations.

Microspheres help microneedles bypass the skin barrier, supporting sustained weekly release with short attachment times.

This case uses a twice-daily 9 or 18 mg PDE4B oral composition to address PF-ILD progression and gastrointestinal side effects.

This case combines EP4 antagonists with checkpoint antibodies, radiation, or antimetabolites to improve anti-tumor activity.

This case pairs CAPRIN-1 antibody therapy with a RET kinase inhibitor to boost phagocytosis and address secondary-mutation resistance.

Structural variations in new compounds inhibit NLRP3 inflammasome activity across immune, metabolic, autoimmune, and cancer disorders.

Vegetable lipid blends deliver DHA-rich omega-3 content with improved oxidative stability.

This case uses crystalline and amorphous Compound (I) forms to inhibit triple-mutant EGFR while limiting wild-type toxicity.

A defined first-lipid-to-sterol ratio supports mRNA and siRNA delivery while addressing toxicity concerns from amino-group lipids.

Mutation testing directs PKC inhibitor treatment for non-uveal melanoma and cancers including pancreatic, colorectal, and lung tumors.

Chemical modifications and GalNAc conjugation strengthen PCSK9 silencing, nuclease stability, and targeted liver delivery.

Pyrimidine compounds target influenza strains resistant to neuraminidase inhibitors.

HMO blends support athlete gut microbiota, immune function, and recovery.

This case uses budesonide, glycerin, and xanthan gum to localize corticosteroid delivery and reduce systemic side effects.

Amide-containing heterocyclic compounds target the PRMT5·MTA complex, inhibiting MTAP-deficient tumors while sparing wild-type cells.

Pyridine-triazole compounds inhibit PHD to stabilize HIFα and induce EPO.

Novel dihydrofuropyridine derivatives improve ROCK inhibitor selectivity and potency.

Gut-targeted NLRP3 antagonists address anti-TNFα resistance while limiting systemic infection risks.

Arginine, polysorbate 80, and pH control stabilize high-concentration BAN2401 formulations for intravenous administration.

This case uses glacial acetic acid to improve ketorolac yield and purity, then applies chiral amine or enzyme resolution for (R)-ketorolac.

This case combines azvudine with chemotherapy to improve tumor control, delay resistance, and reduce harm to normal tissues.

Two overlapping half-shells form a slit-like aperture, combining easier capsule production with stable, targeted mucosal drug release.

This case uses epigenetic regulation by beta-caryophyllene to restore water balance and reduce moisture loss in skin and mucosa.

DHM is combined with matrix materials and plasticizers in HME to improve absorption, stability, and prolonged release.

This case develops a thermally stable AAK1 inhibitor salt form for high-purity manufacture and pharmaceutical formulation.

Separate strands target sense and antisense C9orf72 transcripts, addressing incomplete silencing in mutation-associated ALS and FTD.

This case replaces costly reagents with salt metathesis and crystallization to improve yield, purity, and pharmaceutical suitability.

This case uses selective GDF/BMP antagonists to reduce pulmonary vascular remodeling, muscularization, and PH complications.

CRISPR-edited immune cells resist steroids and calcineurin inhibitors, helping Tregs survive and function during GVHD prophylaxis.

Explore riluzole prodrugs that resist hepatic metabolism and release riluzole in plasma for more predictable ALS treatment.

This case varies molecular substituents and ring systems to improve CGRP receptor antagonist activity and specificity for migraine.

This case uses ionizable, neutral, and sterol lipids to stabilize unshielded nanoparticles while reducing immunogenicity.

This case uses bisaminoquinolines and bisaminoacridines to block autophagy and potentially improve responses to anti-cancer agents.

A separate buffer with controlled pH and osmolality helps keep injectable DMT formulations stable during storage.

This peptide combines receptor-mediated barrier crossing with tumor recognition for brain tumor imaging and drug delivery.

A single-dose aerosol article and closed flow controller regulate heating to make aerosol delivery per puff more consistent.

Controlled 0.5–10 μm particles improve dry-powder dispersibility for lung delivery.

Atropisomeric ATM inhibitors improve kinase selectivity and reduce off-target effects.

This case examines furazidin for bacterial vaginosis, targeting Gardnerella and Atopobium while limiting Lactobacillus depletion.

High-affinity ligands deliver payloads into engineered cells to moderate therapy effects.